[1] S. H. Bae, D. Yim, H. Lee, et al. “Application of Pharmacometrics in Pharmacotherapy: Open-Source Software for Vancomycin Therapeutic Drug Management”. In: Pharmaceutics 11.5 (May. 2019), p. 224. DOI: 10.3390/pharmaceutics11050224. <URL: https://doi.org/10.3390/pharmaceutics11050224>.
[2] S. Cho, S. Han, J. Ghim, et al. “A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males”. In: BioDrugs 33.2 (Mar. 2019), pp. 173-181. DOI: 10.1007/s40259-019-00340-x. <URL: https://doi.org/10.1007/s40259-019-00340-x>.
[3] S. Choi, S. Han, S. Jeon, et al. “Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP)”. In: Pharmaceutics 11.7 (Jul. 2019), p. 336. DOI: 10.3390/pharmaceutics11070336. <URL: https://doi.org/10.3390/pharmaceutics11070336>.
[4] S. Han, S. Han, K. Kim, et al. “Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs”. In: Frontiers in Pharmacology 10 (Nov. 2019). DOI: 10.3389/fphar.2019.01419. <URL: https://doi.org/10.3389/fphar.2019.01419>.
[5] T. M. Polasek, A. Rostami-Hodjegan, D. Yim, et al. “What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing”. In: The AAPS Journal 21.2 (Jan. 2019). DOI: 10.1208/s12248-018-0286-6. <URL: https://doi.org/10.1208/s12248-018-0286-6>.
[6] S. H. Bae, W. Park, S. Han, et al. “Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans”. In: The Korean Journal of Physiology & Pharmacology 22.3 (2018), p. 321. DOI: 10.4196/kjpp.2018.22.3.321. <URL: https://doi.org/10.4196/kjpp.2018.22.3.321>.
[7] S. Choi, S. Jeon, and S. Han. “Population pharmacokinetic analysis of metformin administered as fixed-dose combination in Korean healthy adults”. In: Translational and Clinical Pharmacology 26.1 (2018), p. 25. DOI: 10.12793/tcp.2018.26.1.25. <URL: https://doi.org/10.12793/tcp.2018.26.1.25>.
[8] S. Han, B. Lim, H. Lee, et al. “Development of a user-friendly training software for pharmacokinetic concepts and models”. In: Translational and Clinical Pharmacology 26.4 (2018), p. 166. DOI: 10.12793/tcp.2018.26.4.166. <URL: https://doi.org/10.12793/tcp.2018.26.4.166>.
[9] D. Yim. “Five years of the CiPA project (20132018): what did we learn?” In: Translational and Clinical Pharmacology 26.4 (2018), p. 145. DOI: 10.12793/tcp.2018.26.4.145. <URL: https://doi.org/10.12793/tcp.2018.26.4.145>.
[10] S. Han, G. H. Na, and D. Kim. “A 6-month mixed-effect pharmacokinetic model for post-transplant intravenous anti-hepatitis B immunoglobulin prophylaxis”. In: Drug Design, Development and Therapy Volume 11 (Jul. 2017), pp. 2099-2107. DOI: 10.2147/dddt.s134711. <URL: https://doi.org/10.2147/dddt.s134711>.
[11] W. Huh, H. Oh, J. S. Han, et al. “Hydrochlorothiazide does not increase furosemide's effects in end-stage renal disease”. In: Translational and Clinical Pharmacology 25.1 (2017), p. 28. DOI: 10.12793/tcp.2017.25.1.28. <URL: https://doi.org/10.12793/tcp.2017.25.1.28>.
[12] D. Jang, S. Han, and D. Yim. “Development of an automated appendix generation system (ARGUS) for clinical study reports”. In: Translational and Clinical Pharmacology 25.1 (2017), p. 34. DOI: 10.12793/tcp.2017.25.1.34. <URL: https://doi.org/10.12793/tcp.2017.25.1.34>.
[13] G. Park, S. H. Bae, W. Park, et al. “Drug&ndash$\mathsemicolon$drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer”. In: Drug Design, Development and Therapy Volume11 (Mar. 2017), pp. 1043-1053. DOI: 10.2147/dddt.s131797. <URL: https://doi.org/10.2147/dddt.s131797>.
[14] W. Park, G. Park, S. Han, et al. “Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients”. In: Cancer Chemotherapy and Pharmacology 80.2 (Jun. 2017), pp. 363-369. DOI: 10.1007/s00280-017-3373-y. <URL: https://doi.org/10.1007/s00280-017-3373-y>.
[15] N. Rajasekaran, H. S. Jung, S. H. Bae, et al. “Effect of HPV E6/E7 siRNA with Chemotherapeutic Agents on the Regulation of TP53/E2F Dynamic Behavior for Cell Fate Decisions”. In: Neoplasia 19.10 (Oct. 2017), pp. 735-749. DOI: 10.1016/j.neo.2017.07.005. <URL: https://doi.org/10.1016/j.neo.2017.07.005>.
[16] D. Yim. “Tutorial for beginners: the concept of clearance explained using the example of a vacuum cleaner”. In: Translational and Clinical Pharmacology 25.1 (2017), p. 1. DOI: 10.12793/tcp.2017.25.1.1. <URL: https://doi.org/10.12793/tcp.2017.25.1.1>.